Haematolymphoid Tumours Handbook 2026: A Clinical Textbook Covering Hematopathology, Immunophenotyping, and Molecular Diagnostics for Pathology Fellows

Name: Haematolymphoid Tumours Handbook 2026: A Clinical Textbook Covering Hematopathology, Immunophenotyping, and Molecular Diagnostics for Pathology Fellows
SKU: d759b89142d1b8f125593d87388da44e
Price: 132.87 EUR
Availability: InStock

1/1

Afbeelding van Haematolymphoid Tumours Handbook 2026: A Clinical Textbook Covering Hematopathology, Immunophenotyping, and Molecular Diagnostics for Pathology Fellows

Bol

Prijzen vanaf

132,87

Uitgelicht

	132,87	Naar shop
VERGELIJK ALLE AANBIEDERS (1)

Beschrijving

Bol Know Where WHO-HAEM5 and the ICC Agree, and Exactly Where They Don'tBuilt for the hematopathology fellow and pathology resident reconciling two classification systems at every sign-out, this reference connects normal hematopoiesis and lymphoid development to the morphologic, immunophenotypic, cytogenetic, and molecular criteria that define each entity under both WHO-HAEM5 and the International Consensus Classification. It moves from essential-versus-desirable diagnostic reasoning and flow cytometric lineage assignment through the full range of myeloid, lymphoid, histiocytic, and plasma cell neoplasms to the genetic tumor syndromes that predispose to them. A Dual Classification Crosswalk System, built into every chapter and consolidated into a closing Atlas, names the specific finding each Reporting Anchor requires so the diagnosis holds under either system.At the Scope and in the Report, You Will- Apply essential-versus-desirable reasoning to resolve a case when a cytogenetic study fails or a molecular result is pending. - Score mixed-phenotype acute leukemia and distinguish hematogones from B-lymphoblastic leukemia using the same maturation-gradient logic. - Read a genetically defined AML diagnosis correctly, including the myelodysplasia-related gene and cytogenetic lists where WHO-HAEM5 and the ICC genuinely disagree. - Crosswalk the CML accelerated-phase question and know what to write when a category exists under one classification but not the other. - Diagnose across the mature lymphoma spectrum, CLL through Burkitt and Hodgkin, each anchored to its essential criteria. - Distinguish reversible post-transplant lymphoproliferative disease from the monomorphic lesion that requires conventional treatment. - Recognize favorable pediatric variants, including transient abnormal myelopoiesis, that prevent overtreating a child's disease. - Flag germline TP53, RUNX1, and DDX41 predisposition the moment paired-tissue testing confirms it.Open it before your next sign-out: the classification your patient's diagnosis depends on, resolved either way.

Lees meer

Vergelijk aanbieders (1)

Sorteren op:

€ 132,87 Gratis verzending

Beschrijving (1)

Know Where WHO-HAEM5 and the ICC Agree, and Exactly Where They Don'tBuilt for the hematopathology fellow and pathology resident reconciling two classification systems at every sign-out, this reference connects normal hematopoiesis and lymphoid development to the morphologic, immunophenotypic, cytogenetic, and molecular criteria that define each entity under both WHO-HAEM5 and the International Consensus Classification. It moves from essential-versus-desirable diagnostic reasoning and flow cytometric lineage assignment through the full range of myeloid, lymphoid, histiocytic, and plasma cell neoplasms to the genetic tumor syndromes that predispose to them. A Dual Classification Crosswalk System, built into every chapter and consolidated into a closing Atlas, names the specific finding each Reporting Anchor requires so the diagnosis holds under either system.At the Scope and in the Report, You Will- Apply essential-versus-desirable reasoning to resolve a case when a cytogenetic study fails or a molecular result is pending. - Score mixed-phenotype acute leukemia and distinguish hematogones from B-lymphoblastic leukemia using the same maturation-gradient logic. - Read a genetically defined AML diagnosis correctly, including the myelodysplasia-related gene and cytogenetic lists where WHO-HAEM5 and the ICC genuinely disagree. - Crosswalk the CML accelerated-phase question and know what to write when a category exists under one classification but not the other. - Diagnose across the mature lymphoma spectrum, CLL through Burkitt and Hodgkin, each anchored to its essential criteria. - Distinguish reversible post-transplant lymphoproliferative disease from the monomorphic lesion that requires conventional treatment. - Recognize favorable pediatric variants, including transient abnormal myelopoiesis, that prevent overtreating a child's disease. - Flag germline TP53, RUNX1, and DDX41 predisposition the moment paired-tissue testing confirms it.Open it before your next sign-out: the classification your patient's diagnosis depends on, resolved either way.

Lees meer